Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Heterologous vaccination
Homologous vaccination
Neutralizing antibody
Omicron sublineages
SARS-CoV-2
Journal
Acta tropica
ISSN: 1873-6254
Titre abrégé: Acta Trop
Pays: Netherlands
ID NLM: 0370374
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
28
08
2023
revised:
11
10
2023
accepted:
17
10
2023
medline:
3
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
The Omicron variant is the most divergent, displaying more mutations than previous SARS-CoV-2 variants, particularly in the gene that encodes the spike protein. This study aimed to assess the persistence of neutralizing antibodies towards the SARS-CoV-2 Omicron sublineages (BA.2, BA.5, BQ.1, XBB and XBB1.5) six months after the third dose in different vaccination regimens. Subjects who received 3 doses of mRNA vaccine retained their neutralization activity against BA.2 and BA.5, even though 56.3% and 66.7% showed a ≥ 2-fold reduction in the neutralizing antibody titre, respectively. Subjects who had received the adenovirus-based vaccine plus a booster dose of mRNA vaccine retained their neutralization activity especially against BA.2. With regard to BQ.1, XBB and XBB.1.5, the majority of the subjects showed a ≥ 2-fold reduction in neutralizing antibody titre, with the greatest evasion being observed in the case of XBB. Overall, our results provide further evidence that triple homologous/heterologous vaccination and hybrid immunity result in detectable neutralizing antibodies against the ancestral virus; however, emerging Omicron sublineages, such as XBB and XBB.1.5, show a great evasive capacity, which compromises the effectiveness of current COVID-19 vaccines.
Identifiants
pubmed: 37863379
pii: S0001-706X(23)00228-0
doi: 10.1016/j.actatropica.2023.107042
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
mRNA Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107042Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: C.M.T. is an external consultant of VisMederi Research srl. M.L. and L.B. are employees of VisMederi Research srl. A.M. is an employee of VisMederi srl. E.M. is founder and Chief Scientific Officer of VisMederi srl and VisMederi Research srl. The other authors declare no competing interests.